CHARLOTTES WEB HOLDINGS INC (CWEB.CA) Stock Fundamental Analysis
Canada - TSX:CWEB - CA16106R1091 - Common Stock
0.14 CAD
+0.02 (+12%)
CWEB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 32 industry peers in the Pharmaceuticals industry. CWEB has a bad profitability rating. Also its financial health evaluation is rather negative. CWEB is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CWEB had negative earnings in the past year.
In the past year CWEB has reported a negative cash flow from operations.
CWEB had negative earnings in each of the past 5 years.
CWEB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CWEB's Return On Assets of -24.61% is on the low side compared to the rest of the industry. CWEB is outperformed by 71.88% of its industry peers.
CWEB has a worse Return On Equity (-145.05%) than 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.61% | ||
| ROE | -145.05% | ||
| ROIC | N/A |
ROA(3y)-24.53%
ROA(5y)-32.75%
ROE(3y)-76.52%
ROE(5y)-69.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CWEB has a better Gross Margin (47.67%) than 68.75% of its industry peers.
In the last couple of years the Gross Margin of CWEB has declined.
CWEB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.67% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.4%
GM growth 5Y-4.67%
2. Health
2.1 Basic Checks
CWEB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CWEB has more shares outstanding
Compared to 5 years ago, CWEB has more shares outstanding
Compared to 1 year ago, CWEB has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -4.68, we must say that CWEB is in the distress zone and has some risk of bankruptcy.
CWEB has a worse Altman-Z score (-4.68) than 75.00% of its industry peers.
A Debt/Equity ratio of 3.26 is on the high side and indicates that CWEB has dependencies on debt financing.
CWEB's Debt to Equity ratio of 3.26 is on the low side compared to the rest of the industry. CWEB is outperformed by 84.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.68 |
ROIC/WACCN/A
WACC7.59%
2.3 Liquidity
CWEB has a Current Ratio of 3.83. This indicates that CWEB is financially healthy and has no problem in meeting its short term obligations.
CWEB has a better Current ratio (3.83) than 90.63% of its industry peers.
A Quick Ratio of 1.96 indicates that CWEB should not have too much problems paying its short term obligations.
CWEB has a better Quick ratio (1.96) than 84.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.83 | ||
| Quick Ratio | 1.96 |
3. Growth
3.1 Past
CWEB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.50%, which is quite impressive.
The Revenue has decreased by -7.75% in the past year.
CWEB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -12.09% yearly.
EPS 1Y (TTM)52.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.67%
Revenue 1Y (TTM)-7.75%
Revenue growth 3Y-19.75%
Revenue growth 5Y-12.09%
Sales Q2Q%4.21%
3.2 Future
CWEB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.45% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60%
EPS Next 2Y28.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.9%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CWEB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CWEB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CWEB's earnings are expected to grow with 28.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.45%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CWEB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CWEB (11/18/2025, 7:00:00 PM)
0.14
+0.02 (+12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.76%
Inst Owner ChangeN/A
Ins Owners2.17%
Ins Owner ChangeN/A
Market Cap22.28M
Revenue(TTM)50.32M
Net Income(TTM)-21.66M
Analysts82.86
Price Target0.51 (264.29%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.19%
Min Revenue beat(2)-8.61%
Max Revenue beat(2)-5.76%
Revenue beat(4)0
Avg Revenue beat(4)-11.47%
Min Revenue beat(4)-26.52%
Max Revenue beat(4)-4.98%
Revenue beat(8)0
Avg Revenue beat(8)-16.23%
Revenue beat(12)0
Avg Revenue beat(12)-16.13%
Revenue beat(16)0
Avg Revenue beat(16)-17.05%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.32 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.06 | ||
| P/tB | 1.14 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.44
BVpS0.13
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.61% | ||
| ROE | -145.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.67% | ||
| FCFM | N/A |
ROA(3y)-24.53%
ROA(5y)-32.75%
ROE(3y)-76.52%
ROE(5y)-69.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.4%
GM growth 5Y-4.67%
F-Score4
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.26 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 14.92% | ||
| Cap/Sales | 2.36% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.83 | ||
| Quick Ratio | 1.96 | ||
| Altman-Z | -4.68 |
F-Score4
WACC7.59%
ROIC/WACCN/A
Cap/Depr(3y)21.98%
Cap/Depr(5y)104.62%
Cap/Sales(3y)4.65%
Cap/Sales(5y)9.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.67%
EPS Next Y60%
EPS Next 2Y28.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.75%
Revenue growth 3Y-19.75%
Revenue growth 5Y-12.09%
Sales Q2Q%4.21%
Revenue Next Year7.9%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y50.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-180.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-167.17%
OCF growth 3YN/A
OCF growth 5YN/A
CHARLOTTES WEB HOLDINGS INC / CWEB.CA FAQ
What is the fundamental rating for CWEB stock?
ChartMill assigns a fundamental rating of 2 / 10 to CWEB.CA.
What is the valuation status of CHARLOTTES WEB HOLDINGS INC (CWEB.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to CHARLOTTES WEB HOLDINGS INC (CWEB.CA). This can be considered as Overvalued.
Can you provide the profitability details for CHARLOTTES WEB HOLDINGS INC?
CHARLOTTES WEB HOLDINGS INC (CWEB.CA) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for CWEB stock?
The Earnings per Share (EPS) of CHARLOTTES WEB HOLDINGS INC (CWEB.CA) is expected to grow by 60% in the next year.